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Among 185 cases of gastric cancer and 200 controls in Linxian, China, Epstein–Barr virus (EBV) seropositivity was not associated with
increased risk of gastric cancer. High EBV nuclear antigen titres were associated with longer survival in cardia cancer cases, possibly
due to chance.
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Epstein–Barr virus (EBV), an established cause of lymphoma and
nasopharyngeal carcinoma, has been detected in approximately
10% of gastric tumours (Young and Rickinson, 2004), leading to
speculation that it may also cause gastric cancer.
Previous studies relating EBV to gastric cancer have primarily
been tumour-based. The only previous study of prediagnostic EBV
serology and gastric cancer incidence (Levine et al, 1995) found
generally elevated odds ratios (ORs) for EBV seropositivity and
gastric cancer, but included only 46 cases. No previous study has
evaluated prediagnostic EBV serology and gastric cancer survival.
We prospectively evaluated the associations between baseline
EBV serology in relation to (1) subsequent gastric cancer and (2)
survival among gastric cancer patients in the Linxian General
Population Nutrition Intervention Trial (NIT) cohort in China.
MATERIALS AND METHODS
The NIT was a cancer chemoprevention trial in Linxian, China,
conducted from March 1986 through May 1991, that enrolled
29584 participants (Blot et al, 1993). Follow-up for additional
survival is available through May 2001 (Tran et al, 2005). We
analysed the relation of baseline EBV seropositivity to gastric
cancer incidence in a nested case–control study of cardia cancer
cases (N¼102, a random sample of the 435 cases that arose during
the trial period), non-cardia cancer cases (N¼83), and randomly
selected controls (N¼200). Case and control selection methods
have been described elsewhere (Mark et al, 2000). We also
analysed the association between EBV seropositivity and survival
among gastric cancer cases.
We tested for IgA antibodies against the EBV viral capsid
antigen (VCA IgA) and the diffuse early antigen (EA-D IgA), and
for IgG antibodies against the EBV viral capsid antigen (VCA IgG),
diffuse early antigen (EA-D IgG), restricted early antigen (EA-R
IgG), and EBV nuclear antigen complex (EBNA) using immuno-
fluorescence assays, as previously described (Levine et al, 1995).
EA-D IgA was not detectable. EBV VCA IgA, EA-D IgG, and EA-R
IgG antibodies were detected in o15% of cases and controls and
so were categorised as positive or negative. EBV VCA IgG and
EBNA antibodies, which were detectable in all subjects, were
classified as high if above the median category of antibody titres in
controls and low otherwise. VCA IgG antibody titres were also
analysed ordinally.
Unconditional logistic regression was used to calculate ORs and
95% confidence intervals (CIs) for prediagnostic EBV serostatus
and gastric cancer, controlling for age and gender. Other potential
confounders (e.g., smoking, alcohol, Helicobacter pylori) were
considered but did not affect the estimate for VCA IgG. Kaplan–
Meier curves and age- and gender-adjusted Cox models were used
to evaluate gastric cancer survival by baseline VCA IgG and EBNA.
RESULTS
Cases tended to be older than controls and were more likely to be
males, smokers, and HP positive (Table 1). Among all subjects,
EBV VCA IgA was detectable in 2%, EA-D IgG in 14%, and EA-R
IgG in 9%. VCA IgG EBNA and antibody titre levels were above the
median in the controls in 37% of all subjects.
Overall, prediagnostic EBV seropositivity was not positively
associated with gastric cancer in this population (Table 2). In fact,
the direction and magnitude of the associations suggested that
EBV seropositivity was associated with decreased risk, especially
tumours originating in the gastric cardia. A restricted analysis of
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ycases diagnosed X2 years after serology strengthened the
association for high VCA IgG but not EBNA.
There was no difference in survival by VCA IgG. Survival was
longer among individuals with high vs low EBNA (hazard ratio
(HR): 0.71, 95% CI: 0.51–0.98). This difference was found in cardia
(HR: 0.46, 95% CI: 0.29–0.74) but not in non-cardia cancer cases
(HR: 1.18, HR: 0.74–1.88) (Figure 1). Using the likelihood ratio
test for multiplicative interaction, the HR for baseline EBNA
seropositivity and gastric cancer varied by tumour location
(P-value¼0.03). It is relevant to note, however, that the data
become sparse in the tails of the survival curves, so these findings
may be due to chance.
DISCUSSION
We found that prediagnostic EBV seropositivity was not positively
associated with gastric cancer in this population and rather may be
associated with decreased risk, especially for gastric cardia cancer
which, unusually, is more common than non-cardia gastric cancer
in Linxian (Blot et al, 1993). High baseline EBNA titres were also
associated with decreased risk of death after diagnosis among
gastric cardia cancer cases. Since EBV seropositivity is established
by both viral activity and immune response, these associations
may reflect an increased immune response due to viral infection
leading to reduced gastric cancer incidence and longer survival.
In contrast to our study, the only previous prospective study
reported generally elevated ORs, suggesting an increased risk of
gastric cancer with EBV seropositivity (Levine et al, 1995). The
opposite patterns of risk found in these two studies may be due to
(1) chance, with no true underlying association, (2) differences in
study populations, or (3) different distributions of tumour location
since the previous study included few gastric cardia cancers, while
over half the cases in our study had cardia cancer.
Although previous studies of EBV DNA in gastric tumour tissue
and survival have produced inconsistent results (Chang et al, 2001;
Lee et al, 2004), some have found improved survival associated
with EBV, at least in subgroups (Koriyama et al, 2002; Lee et al,
2004; van Beek et al, 2004). Our association between high EBNA
titres and improved survival was also limited to a subgroup, cardia
cancers, although this finding may be due to chance. Further, we
did not have tumour tissue available to directly test for EBV DNA.
In conclusion, we did not find a positive association between
prediagnostic EBV seropositivity and gastric cancer. In fact, there
was some evidence that EBV seropositivity was associated with a
reduced risk of cancer and a reduced risk of death after diagnosis
of cardia cancer. These results support the hypothesis that cardia
and non-cardia cancers may be aetiologically different and should
be evaluated separately in future studies.
Table 1 Selected characteristics and univariate associations with gastric
cancer for nested case–control subjects from the General Population
Nutrition Intervention Trial cohort
Characteristic N Cases (%) N Controls (%)
Age (years)
o50 32 (17.3) 58 (29.0)
50–60 79 (42.7) 68 (34.0)
460 74 (40.0) 74 (37.0)
Gender
Male 113 (61.1) 98 (49.0)
Female 72 (38.9) 102 (51.0)
Smoking (regularly for X6 months)
No 102 (55.1) 139 (69.5)
Yes 83 (44.9) 61 (30.5)
Alcohol (in last 12 months)
Never/rare 143 (77.3) 160 (80.0)
Sometimes/more often 42 (22.7) 40 (20.0)
Helicobacter pylori
a
Negative 48 (27.8) 73 (45.3)
Positive 125 (72.3) 88 (54.7)
aNumbers do not add up to totals because of missing values.
Table 2 Association between prediagnostic EBV seropositivity and development of gastric cancer in the General Population Nutrition Intervention Trial
cohort for all cases combined and stratified by tumour location
All cases (n¼185) Cardia (n¼102) Non-cardia (n¼83)
EBV variable N positive cases OR (95% CI)
a N positive cases OR (95% CI)
a N positive cases OR (95% CI)
a
VCA IgA positive 3 0.69 (0.15–3.21) 1 0.46 (0.05–4.20) 2 0.90 (0.15–5.40)
EA-D IgG positive 26 0.95 (0.53–1.70) 13 0.82 (0.41–1.67) 13 1.23 (0.58–2.60)
EA-R IgG positive 11 0.52 (0.24–1.11) 6 0.49 (0.19–1.23) 5 0.55 (0.19–1.57)
High VCA IgG
b 60 0.72 (0.47–1.09) 32 0.63 (0.38–1.05) 28 0.83 (0.47–1.46)
Restricted
c 32 0.60 (0.36–0.99) 19 0.54 (0.30–0.99) 13 0.70 (0.33–1.46)
High EBNA IgG 67 0.91 (0.60–1.39) 38 0.97 (0.59–1.60) 29 0.79 (0.45–1.39)
Restricted
c 42 1.01 (0.62–1.64) 26 1.03 (0.59–1.83) 16 0.90 (0.44–1.84)
aAdjusted for age and gender.
bOdds ratios (ORs) for ordinal VCA IgG: all cases, 0.89 (0.78–1.02); cardia cases, 0.86 (0.74–1.00); non-cardia cases, 0.96 (0.80–1.14).
cRestricted
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Figure 1 Kaplan–Meier curves for the proportion of gastric cancer cases
remaining alive by baseline EBV EBNA serostatus and tumour location.
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